Clinical Trial Update: Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) [Phase 3]

View source ↗

Summary

A Phase 3 trial assessed the efficacy and safety of intravitreal aflibercept (EYLEA) for branch retinal vein occlusion; the study completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Branch Retinal Vein Occlusion | Phase 3 | Status: COMPLETED | Results posted: 2014-11-13